Triple Negative Breast Cancer Clinical Trials

Triple Negative Breast Cancer studies recruiting patients for novel treatments. Filter by phase, distance, and inclusion criteria to find your perfect triple negative breast cancer clinical trial.

Filter Clinical TrialsFilter Clinical Trials

LOCATION

Anywhere

CONDITION

Triple Negative Breast Cancer

FILTER TRIALS

This phase II trial studies the side effects and best dose of ivermectin in combination with pembrolizumab and to see how well they they work in shrinking tumors in patients with triple negative breast cancer that has spread to other places in the body (metastatic). Immunotherapy with mono…

Quality of Life Survey

The purpose of this research study is to understand what effect near complete estrogen deprivation (NCED) therapy has on the heart in breast cancer patients. Investigators want to understand if NCED changes how the heart works.

This study will evaluate whether the chemotherapy agent QBS10072S,a.k.a. QBS72S, is effective and safe as a treatment for two types of brain metastases from triple negative breast cancer.

This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC). The first part of the study will determine the safe dose for the nex…

This phase I trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the body (advanced). The experimental vaccine is designed target certai…

NUV-868-01 is a first-in-human, open-label, Phase 1/2 dose escalation and expansion study in patients with advanced solid tumors. The Phase 1 and 1b portions include patients with advanced solid tumors and are designed to determine the safety and the dose of NUV-868 to be used as monothera…

Patients with locally advanced unresectable or metastatic programmed cell death ligand (PD-L1) positive triple negative breast cancer (TNBC) will be treated with radiation to one-four sites of metastasis amenable to radiation (sites of disease to be selected at the discretion of the treati…

This is an open-label, multidose, first-in-human (FIH), Phase 1/2 study of RTX-224 for the treatment of patients with relapsed or refractory (R/R), or locally advanced solid tumors.

This study will test any good and bad effects of combining the study drugs pembrolizumab and olaparib, given before the standard surgical procedure, to treat TNBC or HR+ HER2- breast cancers. The study drugs could shrink cancer, but they could also cause side effects. The study researchers…

This study will test the safety of a drug called SGN-B7H4V in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. Participants will have cancer that has spread in the body near wh…

This phase II trial tests whether panitumumab and pembrolizumab in combination with standard of care chemotherapy before surgery (neoadjuvant) works to shrink tumors in patients with stage III-IV triple negative breast cancer. Panitumumab is a monoclonal antibody that may interfere with th…

This is a Phase 1 dose-escalation study of PRT2527, a Cyclin-dependent Kinase 9 (CDK9) inhibitor, in patients with advanced solid tumors. The purpose of this study is to define the dosing schedule, and maximally tolerated dose to be used in subsequent development of PRT2527.

RAPA-201 Rapamycin Resistant T Cells

The therapy of solid tumors has been revolutionized by immune therapy, in particular, approaches that activate immune T cells in a polyclonal manner through blockade of checkpoint pathways such as PD-1 by administration of monoclonal antibodies. In this study, the investigators will evalua…

Sacituzumab Govitecan-hziy

This is a Phase 2, multicenter, open-label, single arm study evaluating the safety and efficacy of trilaciclib administered prior to sacituzumab govitecan-hziy in patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) who received at least 2 prior t…

The purpose of this study is to evaluate the mechanism of action, as well as the safety and efficacy of trilaciclib in combination with standard of care treatment in the neoadjuvant setting of early-stage triple negative breast cancer (TNBC). This study will have four phases: 1) Screening…

This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with Binimetinib in treating patients with solid tumors that carry RAS alterations and that have spread to other places in the body (advanced/metastatic) or cannot be removed by surgery (unresectab…

This study is evaluating whether a drug called OR2805 can be safely given to people with cancer.

Informational Intervention

This study is evaluating whether a mobile health device can improve adherence to oral chemotherapy in women with triple negative breast cancer.

MDNA11 in combination with checkpoint inhibitor

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

This study is evaluating whether a drug called HMBD-002 can be safely given to people with cancer.

Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody

This study is evaluating whether a virus can be used to treat cancer.

MEM-288 Intratumoral Injection

This phase I trial is designed as an open-label, dose escalation trial of MEM-288 monotherapy in which investigators aim to find the maximum tolerated dose (MTD) and recommended phase II dose (RP2D). Subjects with selected solid tumors including non-small cell lung cancer (NSCLC) who have …

This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors. The aims of the study are: to assess the safety profile of TAK-500 when given alone and when given with pembrolizumab. to assess the effects of TAK-50…

This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.

This research study is being done to find out if the immunotherapy drugs called CDX-301 and CDX-1140 in combination with the standard chemotherapy treatment pegylated liposomal doxorubicin (PLD, Doxil) are safe and effective at controlling the cancer in patients with metastatic triple nega…

Pembrolizumab/Vibostolimab Co-Formulation

This study is evaluating whether a combination of a drug and a light therapy is better than a drug alone in treating cancer.

This is a multicenter, open label, Phase 2 study of TJ004309 in combination with atezolizumab in patients with advanced or metastatic solid tumors.

This study is evaluating whether a new drug called ELU001 can be used to treat cancer.

Stereotactic Body Radiation Therapy

This study is evaluating whether calorie restriction during pre-operative stereotactic ablative radiation therapy (SABR) may decrease tumor tissue in patients with breast cancer.

This study is evaluating whether a drug called magrolimab can improve the effectiveness of chemotherapy in people with breast cancer.

Sacituzumab Govitecan-Hziy

This study is evaluating whether sacituzumab govitecan-hziy is safe and effective in people with triple negative breast cancer.

This study is evaluating whether a new drug can be safely given to people with cancer.

This study is evaluating whether a drug called CMP-001 can be used to treat cancer.

This study is evaluating whether a drug called Niraparib can help treat people with breast cancer.

This study is evaluating whether a drug called TAK-676 can be used to treat cancer.

[18F]FMISO-PET with contrast-enhanced MRI

This study is evaluating whether a new imaging technique may help doctors determine the best treatment for triple negative breast cancer.

This study is evaluating whether there are differences in the effectiveness of surgery for patients with TNBC based on the presence of ctDNA.

Niraparib

Washington, United States

Washington, United States

18+

All Sexes

This research study is looking to see whether the combination of Dostarlimab and Niraparib plus Radiation Therapy (RT) is safe and effective in participants with metastatic triple negative breast cancer. The names of the study treatment involved in this study are: Dostarlimab Niraparib R…

This study is evaluating whether a drug may help treat triple negative breast cancer.

This study is evaluating whether a drug called ST-067 can be safely given to people with cancer.

This study is evaluating whether a blood test can be used to determine whether a specific chemotherapy drug will be effective for a specific individual.

This study is evaluating whether a new drug called TT-00420 is safe and effective for treating cancer.

This study is evaluating whether a drug may help treat solid tumors.

Open label first-in-human study of TH1902 in solid cancer, with 2 sequential parts: Part 1 (dose escalation): patients with recurrent advanced solid tumors (all comers) that have relapsed or are refractory to standard chemotherapy, surgery, radiation therapy, and for which no known effect…

Combination Therapy: PY314 + Pembrolizumab

This study is evaluating whether a drug may help treat cancer.

This is a Phase II study designed to assess efficacy and safety of talazoparib, high dose radiation, and atezolizumab in patients with metastatic TNBC that is PD-L1 positive. A total of 23 gBRCA pathogenic variant negative patients will be enrolled. All patients will be treated with induct…

This study is evaluating whether a drug may help treat triple negative breast cancer.

Standard of Care Neoadjuvant Chemotherapy

This study is evaluating whether vitamin D supplementation during neoadjuvant chemotherapy in operable triple negative breast cancer patients with vitamin D deficiency, will increase the rate of pathologic complete response.

α-lactalbumin vaccine

This study is evaluating whether a protein found in breast milk may help treat breast cancer.

This study is evaluating whether genetically engineered T cells may help treat patients with triple negative breast cancer, urothelial cancer, or non-small cell lung cancer.

Vic-trastuzumab duocarmazine (SYD985) + paclitaxel

This study is evaluating whether a new drug may help treat individuals with breast cancer.

This study is evaluating whether a drug called CX-2009 may help treat breast cancer.

This study is evaluating whether a combination of two drugs may help treat breast cancer.

This study is evaluating whether a drug may help treat cancer.

This study is evaluating whether a drug called fruquintinib can be safely combined with a drug called tislelizumab to treat patients with advanced, refractory triple negative breast cancer.

This clinical trial is evaluating a drug called BT8009 alone and in combination with nivolumab in participants with advanced solid tumors associated with Nectin-4 expression or in participants with advanced solid tumor malignancies having renal insufficiency. The main goals of this study …

PF-07104091 monotherapy dose expansion (ovarian)

This study is evaluating whether a drug may help treat lung, ovarian and breast cancers.

This study is evaluating whether a combination of a drug and monoclonal antibodies may help treat solid tumors.

Cabozantinib S-malate

This study is evaluating whether a combination of two drugs may help treat cancer in patients with HIV.

This study is evaluating whether an antibody-drug conjugate (ADC) which targets a receptor on cancer cells may help treat cancer.

This study is evaluating whether a drug may help treat cancer.

This study is evaluating whether a drug may help treat triple negative breast cancer.

Sacituzumab Govitecan

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this stu…

This study is evaluating whether a drug may help treat breast cancer.

This study is evaluating whether the combination of INCMGA00012 and pelareorep is safe and effective in treating patients with triple negative breast cancer that has spread to other parts of the body (metastatic).

Pembrolizumab

Washington, United States

Washington, United States

18+

All Sexes

This research trial is studying a combination of neoadjuvant radiotherapy (RT), immunotherapy (pembrolizumab) and chemotherapy for lymph node-positive, triple negative (TN) or hormone receptor positive/HER2-negative breast cancer. The names of the study interventions involved in this stud…

This study is evaluating whether a new antibody drug conjugate can be safely given to people with cancer.

Sacituzumab govitecan

This study is evaluating whether a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood.

This study is evaluating whether a combination of two drugs may help treat cancer.

This study is evaluating whether a drug which targets both EGFR and TGFβ may help treat patients with EGFR-driven tumors.

This study is evaluating whether a combination of two drugs may help treat triple negative breast cancer.

This study is evaluating whether a drug may help treat cancer.

This study is evaluating whether a combination of chemotherapy and immunotherapy can improve the outcome of patients with triple negative breast cancer.

This study is evaluating whether a virus which infects cancer cells may help treat cancer.

Anti-HER2/HER3 Dendritic Cell Vaccine

This study is evaluating how well dendritic cell vaccines, CKM regimen, and pembrolizumab work for the treatment of triple negative breast cancer or HER2+ breast cancer that has spread to the brain.

This study is evaluating whether a new treatment may help eliminate minimal residual disease in triple negative breast cancer.

The main purposes of Phase 1b of this study are to determine the following in participants with advanced solid tumors: Safety and tolerability of NT-I7 in combination with pembrolizumab Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) The main purpose of Phase 2a o…

This study is evaluating whether a combination of two drugs may help decrease tumor associated macrophages and increase tumor infiltrating lymphocytes in patients with early stage triple-negative breast cancer.

This study is evaluating whether a drug may help treat cancer.

OC-001 in Combination

This study is evaluating whether OC-001 is effective in treating cancer.

sasanlimab